NAD+ Decline and Aging: The Science Behind NAD-300

NAD+ (nicotinamide adenine dinucleotide) isn't a peptide — it's a coenzyme present in every living cell, essential for mitochondrial function, DNA repair, and cellular energy metabolism. And it declines sharply with age: roughly 50% between age 40 and 60, with the steepest drop in tissues with high metabolic demand — brain, heart, muscle.

This decline is so well-documented that NAD+ restoration has become one of the most active areas in longevity research. Here's what the science actually supports in 2026.

Why NAD+ Declines

The decline isn't from one mechanism — it's a multi-hit process. CD38, an enzyme that consumes NAD+, increases with age and chronic inflammation. DNA damage from accumulated oxidative stress activates PARP enzymes, which also consume NAD+. And the salvage pathway — the body's recycling system for NAD+ precursors — becomes less efficient.

The result is a systemic NAD+ deficit that hits hardest where metabolic demand is highest. Mitochondria — the cellular power plants that depend on NAD+ for the electron transport chain — lose efficiency. Sirtuins, the longevity-associated proteins that require NAD+ as a co-substrate, become less active. DNA repair slows.

NAD+ Precursors: NMN, NR, and NAD-300

Direct NAD+ supplementation doesn't work — the molecule is too large to cross cell membranes efficiently. Instead, the strategy is to supply precursors that cells can convert into NAD+ internally.

Nicotinamide Riboside (NR) is the smallest and most studied precursor. It enters cells through specific transporters and converts to NAD+ through a two-step enzymatic pathway. Clinical trials show NR raises blood NAD+ levels by 40–90% within weeks, with the strongest response in people with the lowest baseline levels.

Nicotinamide Mononucleotide (NMN) is one step closer to NAD+ in the synthesis pathway. It's larger than NR and may require conversion to NR before cellular uptake — the exact transport mechanism is still debated. NMN has shown metabolic benefits in animal models (improved insulin sensitivity, mitochondrial function, exercise capacity) but the human trial data is younger and smaller than NR's.

NAD-300 is the formulation on the Personalized Peptides catalog. It's designed as an injectable NAD+ precursor that bypasses the oral absorption bottleneck — oral NR and NMN face first-pass metabolism in the liver, which reduces the fraction that reaches systemic circulation. The injectable route provides higher bioavailability and more predictable dosing.

What the Evidence Supports

NAD+ restoration — through precursors or direct infusion — has shown consistent effects across three domains:

Mitochondrial function. Improved ATP production, reduced oxidative stress markers, better exercise tolerance in older adults. These are mechanistic benefits — they don't "make you younger" but they improve the cellular machinery that declines with age.

Insulin sensitivity. Multiple trials show improved glucose tolerance and insulin sensitivity with NAD+ precursor supplementation, particularly in prediabetic populations.

Cognitive function. Early but promising — NAD+ restoration improves cerebral blood flow and may slow cognitive decline in mild cognitive impairment. The evidence here is younger than the metabolic data.

What the Evidence Doesn't Support

NAD+ precursors are not "anti-aging drugs" in the regulatory sense. They don't extend lifespan in humans — that data doesn't exist. They don't reverse aging. They restore a coenzyme that declines with age to levels closer to those seen in younger tissue. The gap between "restoring a declining metabolite" and "reversing biological age" is large, and most marketing collapses it.

Cancer risk is the unresolved question. NAD+ fuels both healthy cells and some cancer cells. In theory, boosting NAD+ could accelerate the growth of existing, undiagnosed tumors. The evidence for this is theoretical, not clinical — no trial has shown increased cancer incidence with NAD+ precursors — but the mechanism warrants caution, particularly in individuals with cancer history or strong family history.

For how NAD+ fits into a broader longevity stack, see the NAD-300 product page and the Longevity Stack. For the cycling logic, Cycling Peptides: A Protocol Framework covers cycle length and rest periods. For biological-age tracking, Epigenetic Testing Explained covers how to measure whether your NAD+ protocol is actually working.